ProfileGDS5678 / 1451970_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 91% 88% 89% 88% 90% 91% 88% 88% 86% 87% 88% 88% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9522989
GSM967853U87-EV human glioblastoma xenograft - Control 27.378491
GSM967854U87-EV human glioblastoma xenograft - Control 36.8969188
GSM967855U87-EV human glioblastoma xenograft - Control 47.1685889
GSM967856U87-EV human glioblastoma xenograft - Control 56.9469288
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.0541890
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.2224791
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7449188
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.7619788
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5048586
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.6621687
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0019988
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.816188
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5441986